扎那米韦
医学
奥司他韦
神经氨酸酶抑制剂
优势比
置信区间
神经氨酸酶
传输(电信)
入射(几何)
逻辑回归
内科学
病毒学
病毒
工程类
传染病(医学专业)
物理
疾病
光学
电气工程
2019年冠状病毒病(COVID-19)
作者
Takuji Komeda,Takahiro Takazono,Naoki Hosogaya,Eriko Ogura,Masakazu Fujiwara,Hideyuki Miyauchi,Yoshikazu Ajisawa,Shimpei Iwata,Hideaki Watanabe,Keiichi Honda,Yoshitake Kitanishi,Kanae Hara,Hiroshi Mukae
摘要
Abstract Background Baloxavir marboxil (baloxavir) is expected to reduce influenza transmission by rapid reduction of viral load. The incidence of household transmission was compared between index patients (IPs) treated with baloxavir and those treated with neuraminidase inhibitors. Methods Using a Japanese claims database, the first family members with influenza diagnosis during the 2018–2019 influenza season were identified as IPs, and the diagnosis date was designated day 1. According to the anti-influenza drug dispensed to the IP, their families were classified into the oral baloxavir group and 3 controls: oral oseltamivir group (a primary control), inhaled zanamivir group, and inhaled laninamivir group. A household transmission was defined as influenza diagnosed for any non-IP family members during days 3−8. The incidence of household transmission was compared between groups using a logistic regression model adjusting backgrounds of IPs. Results The proportion of families with household transmission was 17.98% (15 226 of 84 672) in the baloxavir group and 24.16% (14 983 of 62 004) in the oseltamivir group. The covariate-adjusted odds ratio (oseltamivir/baloxavir) was 1.09 (95% confidence interval [95% CI], 1.05–1.12), which indicated significantly lower incidence in the baloxavir group. The adjusted odds ratios (controls/baloxavir) against zanamivir and laninamivir were 0.93 (95% CI, .89–.97) and 0.99 (95% CI, .96–1.02), respectively. Conclusions Baloxavir may contribute to reduction in household transmission compared with oseltamivir. In comparison between baloxavir and inhalants, a similar reduction was not shown and it might be due to unmeasured confounding by administration route differences.
科研通智能强力驱动
Strongly Powered by AbleSci AI